Anti-F8 antibody is a Human antibody of IgG4 κ class that binds to an F8. It developed From patient memory B-lymphocyte cell line.
Figure 1 Inhibition of fVIII functional activity in coagulation assays.
Equal volumes of BO2C11 and of a pool of normal plasma were incubated for 2 hours at 37°C. BO2C11 concentrations before mixing with plasma were as indicated. The residual fVIII activity was measured in an one-stage coagulation assay and was expressed as the percentage of the activity obtained in the absence of antibody.
Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., Bakkus, M., ... & Vermylen, J. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92(2), 496-506.
Figure 2 Time-dependent effect of vWF on fVIII inactivation by BO2C11.
rfVIII alone (solid symbols) or rfVIII complexed with purified vWF (open symbols) was mixed with BO2C11 at either one of two concentrations (see below). The mixture was then incubated at 37°C for various periods of time, from 2 to 60 minutes, after which the residual fVIII activity was evaluated in a chromogenic assay. Results are expressed as the percentage of the activity observed in the absence of antibody. All values are given as final concentrations in the assay system. (•) rfVIII at 60 ng/mL (0.22 nmol/L); (○) rfVIII with vWF at 3 μg/mL (12 nmol/L); (▴) rfVIII + BO2C11 at 85 ng/mL (0.57 nmol/L); (▵) rfVIII-vWF + BO2C11 at 85 ng/mL (0.57 nmol/L); (▪) rfVIII + BO2C11 at 85 μg/mL (570 nmol/L); and (□) rfVIII-vWF + BO2C11 at 85 μg/mL (570 nmol/L).
Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., Bakkus, M., ... & Vermylen, J. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92(2), 496-506.
Figure 3 Kinetics of fVIII/BO2C11 association.
BO2C11 was bound to the sensor chip surface by covalent coupling. Real-time binding was measured for rfVIII at the concentrations indicated. Between each experiment, surface-bound rfVIII was washed off by incubation with HCl, pH 2.0, for 36 seconds. The SPR response gives the amount of surface-bound component at each stage of the reaction, namely (A and B) baseline resonance signal; (B and C) association phase; and (C and D) dissociation phase.
Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., Bakkus, M., ... & Vermylen, J. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92(2), 496-506.
Figure 4 Time-dependent effect of vWF on fVIII inactivation by BO2C11.
rfVIII alone (solid symbols) or rfVIII complexed with purified vWF (open symbols) was mixed with BO2C11 at either one of two concentrations (see below). The mixture was then incubated at 37°C for various periods of time, from 2 to 60 minutes, after which the residual fVIII activity was evaluated in a chromogenic assay. Results are expressed as the percentage of the activity observed in the absence of antibody. All values are given as final concentrations in the assay system. (•) rfVIII at 60 ng/mL (0.22 nmol/L); (○) rfVIII with vWF at 3 μg/mL (12 nmol/L); (▴) rfVIII + BO2C11 at 85 ng/mL (0.57 nmol/L); (▵) rfVIII-vWF + BO2C11 at 85 ng/mL (0.57 nmol/L); (▪) rfVIII + BO2C11 at 85 μg/mL (570 nmol/L); and (□) rfVIII-vWF + BO2C11 at 85 μg/mL (570 nmol/L).
Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., Bakkus, M., ... & Vermylen, J. (1998). Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92(2), 496-506.
Figure 5 Immunoprecipitation of wild-type and mutated rfVIII light chain.
Recombinant fVIII fragments labeled with [35S]methionine and expressed in reticulocyte lysates were incubated for 2 hours at 4°C with LE2E9 (LE) bound to Protein A Sepharose. After washing, bound material was eluted by SDS-buffer and analyzed by SDS-PAGE, followed by autoradiography. Controls included a human monoclonal antibody, BO2C11 (BO), directed toward the fVIII C2 domain,19 a rabbit polyclonal IgG antibody (aA3), directed toward amino acid residues 1797-1815 of the fVIII A3 domain and normal donor polyclonal IgG antibodies (Wi). The experiments were repeated 3 times with similar results.
Jacquemin, M., Benhida, A., Peerlinck, K., Desqueper, B., Vander Elst, L., Lavend'homme, R., ... & Gilles, J. G. (2000). A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood, 95(1), 156-163.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-930-VHH | Recombinant Anti-Human F8 VHH Single Domain Antibody | ELISA, Neut, ICC, FC | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-259CL | Human Anti-F8 Recombinant Antibody (TAB-259CL) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-016WM | Anti-Human F8 Recombinant Antibody (BOIIB2) | Inhib, ELISA | |
TAB-017WM | Anti-Human F8 Recombinant Antibody (4F50) | ELISA | |
TAB-016WM-S(P) | Anti-Human F8 Recombinant Antibody scFv Fragment (BOIIB2) | ELISA | |
TAB-016WM-F(E) | Anti-Human F8 Recombinant Antibody Fab Fragment (BOIIB2) | ELISA | |
TAB-017WM-F(E) | Anti-Human F8 Recombinant Antibody Fab Fragment (4F50) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-014LC | Recombinant Anti-Human F8 Antibody (Fab glycosylation) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
Gly-015LC | Recombinant Anti-Human F8 Antibody (Non-glycosylated) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
PABX-058-S (P) | Recombinant Human Anti-F8 Antibody scFv Fragment (BO2C11) | WB, ELISA, FuncS | scFv |
PABX-058-F (E) | Recombinant Human Anti-F8 Antibody Fab Fragment (BO2C11) | WB, ELISA, FuncS | Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-765CQ | Mouse Anti-F8 Recombinant Antibody (clone CBL215) | ELISA, WB, Neut | Mouse IgG2a |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1229 | Hi-Affi™ Rabbit Anti-F8 Recombinant Antibody (clone DS1229AB) | ELISA | Rabbit IgG |
MOR-4166 | Hi-Affi™ Rabbit Anti-F8 Recombinant Antibody (clone SI243DS) | ELISA | Rabbit IgG |
MOR-4167 | Hi-Affi™ Rabbit Anti-F8 Recombinant Antibody (clone SI244DS) | ELISA | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
EPAF-0611LC | Human Anti-F8 Recombinant Antibody (clone BO2C11) | ELISA | Human IgG4 |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0096-YC | Human Anti-F8 Recombinant Antibody (clone YK3.3.38) | ELISA, FuncS | Human IgG |
HPAB-0793-FY | Mouse Anti-F8 Recombinant Antibody (clone 4F143) | Activ | Mouse IgG |
HPAB-0794-FY | Mouse Anti-F8 Recombinant Antibody (clone 4F50) | Activ | Mouse IgG |
HPAB-1977-FY | Human Anti-F8 Recombinant Antibody (clone 92-137) | Inhib | Human IgG |
HPAB-1978-FY | Human Anti-F8 Recombinant Antibody (clone 92-102) | Inhib | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0197-CN-F(E) | Human Anti-F8 Recombinant Antibody (clone KM33); Fab Fragment | WB | Human Fab |
HPAB-1977-FY-F(E) | Human Anti-F8 Recombinant Antibody (clone 92-137); Fab Fragment | Inhib | Human Fab |
HPAB-1978-FY-F(E) | Human Anti-F8 Recombinant Antibody (clone 92-102); Fab Fragment | Inhib | Human Fab |
HPAB-1979-FY-F(E) | Human Anti-F8 Recombinant Antibody (clone WR8); Fab Fragment | IP | Human Fab |
HPAB-1980-FY-F(E) | Human Anti-F8 Recombinant Antibody (clone WR11); Fab Fragment | IP | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
MHC-YF075 | DRB1*11:01/Factor VIII Factor VIII (ENIQRFLPNPAGVQLEDPEF) MHC Monomer | MHC Multimer |
CAT | Product Name | Application | Type |
---|---|---|---|
FAMAB-0037JF-S(P) | Human Anti-F8 Recombinant Antibody (clone MH8); scFv Fragment | IP, ELISA, FuncS | Human scFv |
FAMAB-0038JF-S(P) | Human Anti-F8 Recombinant Antibody (clone DH10); scFv Fragment | IP, ELISA, FuncS | Human scFv |
FAMAB-0039JF-S(P) | Human Anti-F8 Recombinant Antibody (clone JM4); scFv Fragment | IP, ELISA, FuncS | Human scFv |
FAMAB-0286JF-S(P) | Human Anti-F8 Recombinant Antibody (clone VK34); scFv Fragment | ELISA, FuncS | Human scFv |
FAMAB-0287JF-S(P) | Human Anti-F8 Recombinant Antibody (clone VK41); scFv Fragment | ELISA, FuncS | Human scFv |
There are currently no Customer reviews or questions for PABX-058. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.